Literature DB >> 19175523

Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study.

Chi-Ping Day1, John Carter, Carrie Bonomi, Dominic Esposito, Bruce Crise, Betty Ortiz-Conde, Melinda Hollingshead, Glenn Merlino.   

Abstract

Lentiviral vectors (LVs) are capable of labeling a broad spectrum of cell types, achieving stable expression of transgenes. However, for in vivo studies, the duration of marker gene expression has been highly variable. We have developed a series of LVs harboring different promoters for expressing reporter gene in mouse cells. Long-term culture and colony formation of several LV-labeled mouse melanoma cells showed that promoters derived from mammalian house-keeping genes, especially those encoding RNA polymerase II (Pol2) and ferritin (FerH), provided the highest consistency for reporter expression. For in vivo studies, primary B16BL6 mouse melanoma were infected with LVs whose luciferase-green fluorescence protein fusion gene (Luc/GFP) was driven by either Pol2 or FerH promoters. When transplanted into syngeneic C57BL/6 mice, Luc/GFP-labeled B16BL6 mouse melanoma cells can be monitored by bioluminescence imaging in vivo, and GFP-positive cells can be isolated from the tumors by fluorescence-activated cell sorter. Pol2-Luc/GFP labeling, while lower in activity, was more sustainable than FerH-Luc/GFP labeling in B16BL6 over consecutive passages into mice. We conclude that Pol-2-Luc/GFP labeling allows long-term in vivo monitoring and tumor cell isolation in immunocompetent mouse melanoma models.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19175523      PMCID: PMC2726997          DOI: 10.1111/j.1755-148X.2009.00545.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  33 in total

1.  Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9.

Authors:  Vesco Mutskov; Gary Felsenfeld
Journal:  EMBO J       Date:  2003-12-11       Impact factor: 11.598

2.  From lentiviruses to lentivirus vectors.

Authors:  Maurizio Federico
Journal:  Methods Mol Biol       Date:  2003

3.  Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression.

Authors:  Martine Latta-Mahieu; Magali Rolland; Catherine Caillet; Manping Wang; Philippe Kennel; Irene Mahfouz; Isabelle Loquet; Jean-François Dedieu; Abderrahim Mahfoudi; Emanuelle Trannoy; Vincent Thuillier
Journal:  Hum Gene Ther       Date:  2002-09-01       Impact factor: 5.695

Review 4.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

5.  Biological behavior of malignant melanoma cells correlated to their survival in vivo.

Authors:  I J Fidler
Journal:  Cancer Res       Date:  1975-01       Impact factor: 12.701

6.  Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis.

Authors:  Juan A Recio; Frances P Noonan; Hisashi Takayama; Miriam R Anver; Paul Duray; Walter L Rush; Gerd Lindner; Edward C De Fabo; Ronald A DePinho; Glenn Merlino
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

7.  Liver-directed gene therapy: quantitative evaluation of promoter elements by using in vivo retroviral transduction.

Authors:  S D Rettinger; S C Kennedy; X Wu; R L Saylors; D G Hafenrichter; M W Flye; K P Ponder
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

8.  Cre-lox-regulated conditional RNA interference from transgenes.

Authors:  Andrea Ventura; Alexander Meissner; Christopher P Dillon; Michael McManus; Phillip A Sharp; Luk Van Parijs; Rudolf Jaenisch; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-06       Impact factor: 11.205

9.  Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice.

Authors:  Antonia Follenzi; Manuela Battaglia; Angelo Lombardo; Andrea Annoni; Maria Grazia Roncarolo; Luigi Naldini
Journal:  Blood       Date:  2003-12-30       Impact factor: 22.113

10.  Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection.

Authors:  J S Weber; G Jay; K Tanaka; S A Rosenberg
Journal:  J Exp Med       Date:  1987-12-01       Impact factor: 14.307

View more
  27 in total

1.  MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms.

Authors:  Y-N Liu; J J Yin; W Abou-Kheir; P G Hynes; O M Casey; L Fang; M Yi; R M Stephens; V Seng; H Sheppard-Tillman; P Martin; K Kelly
Journal:  Oncogene       Date:  2012-02-27       Impact factor: 9.867

2.  Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.

Authors:  Nan Li; Haiying Fu; Stephen M Hewitt; Dimiter S Dimitrov; Mitchell Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

3.  T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS Oncogenesis.

Authors:  Christophe Cataisson; Rosalba Salcedo; Aleksandra M Michalowski; Mary Klosterman; Shruti Naik; Luowei Li; Michelle J Pan; Amalia Sweet; Jin-Qiu Chen; Laurie G Kostecka; Megan Karwan; Loretta Smith; Ren-Ming Dai; C Andrew Stewart; Lyudmila Lyakh; Wang-Ting Hsieh; Asra Khan; Howard Yang; Maxwell Lee; Giorgio Trinchieri; Stuart H Yuspa
Journal:  Mol Cancer Res       Date:  2019-06-04       Impact factor: 5.852

4.  Distinct microRNA expression signatures are associated with melanoma subtypes and are regulated by HIF1A.

Authors:  Hun-Way Hwang; Laura L Baxter; Stacie K Loftus; Julia C Cronin; Niraj S Trivedi; Bhavesh Borate; William J Pavan
Journal:  Pigment Cell Melanoma Res       Date:  2014-05-27       Impact factor: 4.693

5.  Assessment of Immune Isolation of Allogeneic Mouse Pancreatic Progenitor Cells by a Macroencapsulation Device.

Authors:  Gaetano Faleo; Karim Lee; Vinh Nguyen; Qizhi Tang
Journal:  Transplantation       Date:  2016-06       Impact factor: 4.939

6.  Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor β-initiated prostate cancer epithelial-mesenchymal transition.

Authors:  Yen-Nien Liu; Wassim Abou-Kheir; Juan Juan Yin; Lei Fang; Paul Hynes; Orla Casey; Dong Hu; Yong Wan; Victoria Seng; Heather Sheppard-Tillman; Philip Martin; Kathleen Kelly
Journal:  Mol Cell Biol       Date:  2011-12-27       Impact factor: 4.272

7.  Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases.

Authors:  Karianne G Fleten; Kine M Bakke; Gunhild M Mælandsmo; Andreas Abildgaard; Kathrine Røe Redalen; Kjersti Flatmark
Journal:  Clin Exp Metastasis       Date:  2016-11-03       Impact factor: 5.150

8.  Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin.

Authors:  Chi-Ping Day; John Carter; Carrie Bonomi; Melinda Hollingshead; Glenn Merlino
Journal:  Int J Cancer       Date:  2011-04-20       Impact factor: 7.396

9.  Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer.

Authors:  Aria Vaishnavi; Michael T Scherzer; Conan G Kinsey; Gennie L Parkman; Amanda Truong; Phaedra Ghazi; Sophia Schuman; Benjamin Battistone; Ignacio Garrido-Laguna; Martin McMahon
Journal:  Cell Rep       Date:  2020-08-04       Impact factor: 9.423

10.  TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.

Authors:  John K Simmons; Jyoti Patel; Aleksandra Michalowski; Shuling Zhang; Bih-Rong Wei; Patrick Sullivan; Ben Gamache; Kenneth Felsenstein; W Michael Kuehl; R Mark Simpson; Adriana Zingone; Ola Landgren; Beverly A Mock
Journal:  Mol Oncol       Date:  2013-12-03       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.